Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

13-week, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Modified Release AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

This study will assess the efficacy and safety of modified release AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

Inclusion Criteria:

• Males and Females 30-80 years old
• Use of highly effective methods of contraception during study in women of childbearing potential
• Outpatients
• Clinical diagnosis of Parkinson's Disease according to UK Parkinson's Disease Society Brain Bank Clinical Diagnosis criteria
• Score of >/= 2 on UPDRS items 32 and 33
• Dyskinesias for at least 3 months before baseline
• On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline
• Demonstrate capacity to complete accurate diary ratings
• Patients who have a primary caregiver willing to assess the condition of the patient throughout the study in accordance with protocol requirements
• Group 2 only: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study

Exclusion Criteria:

• Atypical/secondary form of Parkinson's disease
• History of surgical treatment of PD, including deep brain stimulation
• A score of 5 in the "ON"- state on the Modified Hoehn and Yahr scale
• Advanced, severe, or unstable disease other than PD
• Evidence of dementia
• Treatment with certain prohibited medications
• Amantadine within 2 weeks prior to BL1 visit (applies to Group 1 only)

Other protocol-defined inclusion/exclusion criteria may apply.